TrialDiabetes care2011

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.

Bertrand Cariou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.